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Occult hepatitis B virus (HBV) infections have been identified in patients with chronic hepatitis
C virus (HCV) infection, although the clinical relevance of occult HBV infection remains
controversial. We searched for serum HBV DNA in 106 HBsAg negative/anti-HBc positive patients
with chronic HCV infection and in 150 blood donors HBsAg negative/anti-HBc positive/anti-HCV
negative (control group) by nested-PCR. HCV genotyping was done in 98 patients and percutaneous
needle liver biopsies were performed in 59 patients. Fifty-two patients were treated for HCV
infection with interferon alone (n=4) or combined with ribavirin (n=48) during one year. At the
end and 24 weeks after stopping therapy, they were tested for HCV-RNA to evaluate the sustained
virological response (SVR). Among the 106 HCV-positive patients, 15 (14%) were HBV-DNA
positive and among the 150 HCV-negative blood donors, 6 (4%) were HBV-DNA positive. Liver
biopsy gave a diagnosis of liver cirrhosis in 2/10 (20%) of the HBV-DNA positive patients and in
6/49 (12%) of the HBV-DNA negative patients. The degree of liver fibrosis and portal inflammation
was similar in HCV-infected patients HBV-DNA, irrespective of HBV-DNA status. SVR was
obtained in 37.5% of the HBV-DNA positive patients and in 20.5% of the HBV-DNA negative
patients; this difference was not significant. In conclusion, these data suggested that occult HBV
infection, which occurs at a relatively high frequency among Brazilian HCV-infected patients,
was not associated with more severe grades of inflammation, liver fibrosis or cirrhosis development
and did not affect the SVR rates when the patients were treated with interferon or with interferon
plus ribavirin.
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Hepatitis B virus (HBV) is an important human
pathogen that causes both acute disease and chronic
infection. Studies based on serological assays for HBV
have led to the concept that HBV is eliminated after the
resolution of an acute infection [1], although a chronic
carrier state [2-4], defined as being positive for hepatitis
B surface antigen (HBsAg) for at least six months [5-7],
has been reported to occur in about 5% of affected adults
[8]. During acute and chronic HBV infections, antibodies
against the core antigen of HBV (anti-HBc) are found
together with HBsAg, whereas in resolved infections they
are accompanied by antibodies against HBsAg (anti-
HBs). About 10-20% of all individuals with hepatitis B
have anti-HBc as the only marker of HBV infection [9].
In about 10% of these individuals HBV-DNA can be
detected by a PCR assay [9,10]. HBV infection may
also occur in HBsAg-negative patients who have
serological markers of previous infection (anti-HBs) [11].
These HBV infections in patients who lack detectable
HBsAg are called occult infections [11]; the serum HBV-
DNA levels are usually less than 104 copies/mL [12].
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Recently, very low levels of HBV-DNA have also
been identified in the sera of patients with chronic
hepatitis C virus (HCV) infection, even though there is
no HBsAg in the serum [11,13,14-18]. It appears that
this occult infection contributes to chronic liver damage
and to the development of hepatocellular carcinoma
[11,15,19-22]. Occult HBV infection can also be
associated with a lack of response to interferon
treatment in patients with chronic hepatitis C [11,18].
Recently, we used PCR to study the prevalence of
occult HBV infection in serum samples of 106 patients
with chronic HCV infection who were both HBsAg
negative and anti-HBc positive. HBV-DNA was
detected in 15 (14%) of them [23].
We evaluated how occult HBV infection influences
epidemiological, laboratorial, histological and
therapeutic features of Brazilian HCV-infected patients.
Material and Methods
Between March 2000 and May 2002, we selected
106 patients who had been infected by HCV (anti-
HCV and HCV-RNA positive) and who were being
followed-up at the University Hospital of UNICAMP.
None of the patients had detectable HBsAg or were
infected by human immunodeficiency virus (HIV). All
of them had serum markers of previous HBV infection:
all were anti-HBc positive and 56 (53%) were also
anti-HBs positive. In the first phase these selected
patients were tested for HBV-DNA by an “in house”
nested-polymerase chain reaction (nested-PCR) [23].
To estimate the viral load of the samples determined
positive for HBV-DNA by “in house” PCR, a
commercial test for HBV-DNA (HBV Monitor Roche,
Roche Diagnostic Systems, Branchburg, NJ), with a
lower detection limit of 1,000 copies/mL, was used.
Based on the nested-PCR results the patients
were divided into two groups: one group was HCV
positive/HBV DNA positive (n=15) and the other
was HCV positive/HBV DNA negative (n=91). The
HCV genotype was determined in the serum of 98
patients, before initiating specific therapy for HVC
infection.
Percutaneous needle biopsies of the liver were made
in 59/106 patients, in order to evaluate the degree of
histological lesion. All liver biopsy specimens were
fixed, paraffin embedded, and stained with
hematoxylin-eosin safranin and Masson trichrome for
histological and immunohistochemical examination. A
numerical score was calculated for each liver biopsy
specimen, both for grading necroinflammatory activity
and for determining the degree of fibrosis. The patients
were divided into three categories according to the
histological findings: those with minimal or non-specific
changes, those with mild-to-moderate chronic hepatitis,
and those with severe chronic hepatitis, with features
of cirrhosis. The stage of fibrosis was determined
according to METAVIR score and varied from 0 to 4
(F0 = no fibrosis; F1 = portal fibrosis without septa;
F2 = portal fibrosis with few septa; F3 = septal fibrosis,
without cirrhosis; F4 = cirrhosis) [11, 24, 25].
A control group to compare the epidemiological data
was constituted of 150 blood donors who were HBsAg
negative/ anti-HBc positive in blood bank screening.
To identify occult HBV infection among these controls,
we also tested these samples with “in house” nested-
PCR [23], and we used a commercial test for HBV-
DNA (HBV Monitor Roche, Roche Diagnostic
Systems, Branchburg, NJ) with a lower detection limit
of 1,000 copies/mL to estimate the viral load of these
positive samples.
Based on PCR results the controls were subdivided
into: one group that was HCV negative/HBV-DNA
positive (n=6) and another group that was HCV
negative/HBV-DNA negative (n=144).
All the HCV-infected and control individuals were
interviewed with a questionnaire to investigate risk
factors to acquire these viruses. This questionnaire
included questions about age, sex, sexual contacts,
transfusions of blood or derivatives, use of illicit drugs
by intravenous routes, tattooing, and acupuncture.
At the end of the study, 52 patients had completed
the treatment for HCV infection, and they were
followed up for 24 weeks after ending therapy. These
patients were treated with interferon a-2a 3 MU t.i.w,
alone (n=4) or combined with ribavirin (1,000-1,200
mg/daily) (n=48) during one year. During the entire
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follow-up period the ALT/AST levels were measured
to evaluate the biochemical response. At the end of
therapy, and 24 weeks later, the serum of these patients
was tested for HVC-RNA. Patients who were HCV-
RNA negative 24 weeks after the end of therapy, were
considered to have a sustained virological response
(SVR). Virological testing was done in accordance with
the ethical guidelines of the authors´ institutions.
Serum markers for HBV, HIV and HCV infection
Serum HBsAg and anti-HBc were evaluated with
commercial immunoenzymatic assays (Hepanostika
HBsAg Uniform II and Hepanostika anti-HBc Uniform;
Organon Teknika, Boxtel, Netherlands, respectively)
and were tested for anti-HBs (AUSAB MEIA, Abbott
Laboratories, North Chicago, IL), anti-HCV (anti-
HCV assay version 3.0; Abbott Murex, Dartford, UK),
and anti-HIV (anti-HIV1.2.O assay; Abbott
Murex,Dartford, UK). HCV infection was defined as
the presence of anti-HCV antibodies and HCV-RNA
(HCV-AMPLICOR, Roche Diagnostic Systems,
Branchburg, NJ) in the serum. The HCV genotype was
determined by a commercial assay (INNO LIPA
Innogenetics, Belgium) before starting interferon
therapy. All the assays were performed according to
manufacturers instructions.
Detection of Hepatitis B virus DNA in the serum
The nested-PCR method for detection of HBV
DNA was performed essentially as described
previously by KANEKO et al [26,27]. A 10 mL
aliquot of serum was pipetted into a 0.2 mL micro
centrifuge tube. The serum was then incubated with
2.5mL of 0.5M NaOH at 37oC for 60 minutes. After
incubation, the solution was brought to a neutral pH
with 0.5M HCl, and the sample was used for PCR
amplification of HBV DNA sequences. The samples
were amplified in a 100mL reaction volume
containing 2.5 U of Taq polymerase (Bethesda
Research Laboratories, Life Technologies Inc.,
Gaithersburg, Maryland), 200mM each of the four
deoxyribonucleic triphosphates, 1mM of the primer
pair (primers 1763 5’-
GCTTTGGGGCATGGACATTGACCCGTATAA-
3’ and 2032R 5’-
CTGACTACTAATTCCCTGGATGCTGGGTCT-





The amplification routine was: 25 cycles;
1.5 minutes at 94oC, 1.5 minutes at 42oC and 3
minutes at 72oC, in a DNA Thermal Cycler (Perkin
Elmer Cetus, Foster City, Ca, USA). For
reamplification, a 10mL aliquot of the primary PCR
reaction was amplified as described above, using
primer pair (1778-E 5’-
GACGAATTCCATTGACCCGTATAAAGAATT-
3’ and 2017R-B 5’-
ATGGGATCCCTGGATGCTGGGTCTTCCAAA-
3’). An aliquot of water was used as a negative
control and serum from an HBV positive individual
according to EIA quantified with the Amplicor HBV
Monitor test (Roche Diagnostic Systems,
Branchburg, NJ) (1.0 X 102 copies/mL) was used
as a positive control. Serial dilutions were made in
an HBsAg low-titer performance panel (PHA 105;
Boston Biomedica, Inc., Boston, Mass), with which
we determined the detection limit of our nested PCR
as being 102 copies/mL. Carryover contamination
was prevented as described by KWOK& HIGUCHI
[28]. The final amplification product was mixed with
bromphenol blue, eletrophoresed in a 2% agarose
gel, visualized by UV fluorescence after staining with
ethidium bromide, and photographed with Polaroid
film. Samples were considered positive if they yielded
at least two positive results from three amplifications.
Samples were considered negative when there were
two negative results in two different reactions.
Statistical analysis
The student’s t-test and the Mann-Whitney test
were used to analyze quantitative data. Fischer’s exact
test was used to analyze quantitative data and for
comparing proportions [29]. All calculated p values
were two-tailed; a p value < 0.05 was considered
significant.
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Results
The demographic characteristics and risk factors
for HCV infection are shown in Table 1. Among our
106 HCV-infected patients, 88 (83%) were male and
18 (17%) females. In the HBV-DNA positive group
11/88 (12.5%) were men and 4/18 (22%) women
(p>0.05). The median age was 47.2 ± 9.7 years among
HCV positive/HBV-DNA positive patients and was
46.4 ± 9.3 years among HCV positive/HBV-DNA
negative patients (p>0.05). Among the 150 HCV-
negative blood donors, 101 (67%) were male and 49
(33%) were females. HBV-DNA was found in 4/101
(4%) men and in 2/49 (4%) women (p>0.05). The
median age was 33.8 ± 11.8 years in the HCV negative/
HBV-DNA positive blood donors and was 39.8 ± 10.8
years in the HCV negative/HBV-DNA negative blood
donors (p>0.05). There was no significant association
of sex or age and HBV-DNA in either group.
In the analysis of risk factors, among the 106 HCV-
infected patients, 34 (32%) were intravenous drug users
(IVDU); 23 (21.7%) had received blood transfusion,
20 (18.9%) had surgery, 2 (1.9%) reported unsafe
sexual contact, 2 (1.9%) reported more than 1 risk
factor (tattoo and acupuncture), and 25/106 (23.6%)
denied risk factors. Among the 150 HCV-negative/anti-
HBc positive blood donors 8 (5.3%) were IVDU;
17(11.3%) had received a blood transfusion, 1 (0.7%)
had surgeries, 46 (30.7%) indicated sexual contact as
a risk factor, 10 (6.7%) reported more than 1 risk factor
and 68 (45.3%) denied any risk factors for HCV
infection. No significant association was found between
risk factors and HBV-DNA presence.
Among the blood donors, 5.3% were IVDU, while
32% of the HCV-positive group were IVDU (p<0.05).
Unsafe sexual practice was reported by 1.9% of the
HCV-positive group and in 30.7% of the blood donors
(p<0.05). When all sub-groups (HBV-DNA negative
or positive) were compared, significant differences
among risk groups were found for virus acquisition,
mainly because there were more IVDU in the HCV-
positive group, with or without occult HVB infection,
when compared with the group of blood donors who
were HBV-DNA negative (Table 1).
We were able to determine the HCV genotype in 98
HCV-positive patients. Genotype 1 was encountered in
62/98 (63%), genotype 2 in 1/98 (1%), genotype 3 in
32/98 (33%) and genotype 1 and 3 in 3/98 (3%). The
frequencies of the different HCV genotypes were similar
in HCV-positive patients with and without occult HBV
infection (p>0.05, Table 2).
Liver biopsies were taken from 59 HCV-positive
patients. Among them 2 (3%) presented minimal
changes, 49 (83%) had chronic hepatitis and 8 (14%)
had liver cirrhosis. Liver cirrhosis was diagnosed in 2/10
(20%) of the HBV-DNA positive patients and in 6/49
(12%) of the HBV-DNA negative patients (p>0.05).
HBV-DNA presence was not significantly associated with
more advanced histological lesions in the liver in HCV-
positive patients (p>0.05, Table 2). Liver fibrosis and
portal inflammation were found at similar rates in HCV-
infected patients with or without HBV-DNA positive in
serum (p>0.05, Table 3). Immunohistochemical staining
was negative for HBsAg and HBcAg in all liver biopsies
from HCV positive/HBV-DNA positive patients. Fifty-
two HCV-positive patients were treated with interferon
(n = 4) or with a combination of interferon plus ribavirin (n
= 48) during 48 weeks. No significant differences were
found in the rates of biochemical or virological responses
in the HCV-infected patients with or without HBV-DNA
in the sera (p>0.05, Table 4).
Discussion
Initially, we looked for occult HBV infection in
HBsAg negative/anti-HBc positive individuals, with and
without chronic HCV infection. This population of
HCV-infected patients and blood donors is
representative of the general population in our region.
We found that 14% of the HCV-infected patients had
detectable HBV genome in their serum. This prevalence
was significantly higher than that found among HCV-
negative individuals (4%) [23]. The reasons for the
disappearance of HBsAg and, in some cases, of all
HBV markers, despite the persistence of HBV infection,
are not completely understood. Some researchers
consider that HBV could be present at very low levels,
Occult B Infection in Chronic HCV Patients
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Table 1. Characteristics and risk factors in hepatitis C virus (HCV)-infected patients divided according to hepatitis
B virus (HBV)-DNA positivity
Table 2. Hepatitis C virus (HCV) genotypes and histological diagnosis in HCV-positive patients, divided according
to HBV-DNA positivity in the serum
Occult B Infection in Chronic HCV Patients
Characteristic HCV (+) / anti-HBc (+) HCV (-) / anti-HBc (+)
 HBV-DNA (+) HBV-DNA (-) Total HBV-DNA (+) HBV-DNA (-) Total
n=15 n =91 n =106 n =6 n =144 n =150
Mean age (yr) 47.2 ± 9.7 46.4 ± 9.3 46.8 ± 9.5 33.8 ± 11.8 39.8 ± 10.8 36.8 ± 11.3
Sex (M/F) 11/4 77/14 88/18 4/2 97/47 101/49
Risk Factors n (%) n (%) n (%) n (%) n (%) n (%)
IVDU 4/15 (26.7) 30/91 (33) 34/106 ( 32 ) 1/69 (16.7) 7/144 (4.9 ) 8/150 (5.3)
Transfusion  3/15 (20)  20/91 (22) 23/106 (21.7)  - - 17/144 (11.8) 17/150 (11.3)
Surgery 4/15 (26.7) 16/91 (17.6) 20/106 (18.9)  - - 1/144(0.7 ) 1/150 (0.7)
Unsafe sexual - -  2/91 (2.2)  2/106 (1.9)  1/6 (16.7)  45/144 (31.2) 46/150 (30.7)
practices
Not determined 4/15 (26.6)  21/91 (23) 25/106 (23.6) 4/6 (66.6)  64/144 (44.5) 68/150 (45.3)
Others*  - -  2/91 (2.2)  2/106 (1.9)  - -  10/144** (6.9 ) 10/150 (6.7)
*Tattoo/acupuncture. **Transfusion/Sexual. IVDU: Intravenous drug use. p>0.05 for comparison of HBV-DNA(+)/HBV-DNA(-) patients
in both groups. P<0.05 when all sub-groups (HBV-DNA negative or positive) are compared.
Variable HBV DNA (+) HBV DNA (-)
n=14 n=84
Genotype n (%) n (%)
1 9 (64) 53 (63)
2 - - 1 (1.2)
3 5 (36) 27 (32)
1+3 - - 3 (3.6)
HBV DNA (+) HBV DNA (-)
n=10  n=49
Histological diagnosis n (%)  n (%)
Minimal changes 1 (10) 1 (2)
Chronic hepatitis (mild/severe) 7 (70) 42 (86)
Cirrhosis 2 (20) 6 (12.3)
P>0.05 for comparison of patients HBV-DNA(+)/HBV-DNA(-).
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Table 3.Histopatological alterations observed in liver biopsies from 59 patients with chronic hepatitis C
Table 4. Response to interferon treatment in patients with chronic hepatitis C virus infection, with and without
occult hepatitis B virus (HBV) infection
undetectable by conventional serological assays. The
HBsAg could elude detection by the polyclonal
antibody used in conventional assays in the presence
of HBsAg or HBsAg/anti-HBs immune complexes [30].
It is also possible that virions that are not
transcriptionally active or replicating, quiescent or latent
virions, are able to evade the surveillance of host
immune cells [31]. Hepatocytes could be repeatedly
re-infected by HBV virions, which could persist
independently in peripheral blood mononuclear cells,
or in other lymphoid tissues [10, 32]. We found that
HBV-DNA persisted at low levels in patients with
apparently resolved HBV infection. We utilized a highly
s nsitive in-house PCR test with a detection limit of
100 copies/mL [23]. The positive samples were tested
afterwards with a commercial test that had a detection
limit of 1,000 copies/mL, and all were negative. Thus,
our HBV-DNA-positive patients, and the blood donors
of the control group, had more than 100 and less than
1,000 copies/mL, which indicates that low levels of
HBV-DNA are generally present in the sera of patients
with occult HBV infection.
Occult B Infection in Chronic HCV Patients
Liver histology HBV-DNA (+) HBV-DNA (-)
 n=10  n=49
Fibrosis n (%) n (%)
No fibrosis (F0) 1 (10)  4 (8.2)
Portal fibrosis without septa (F1) 2 (20) 15 (31)
Portal fibrosis with few septa (F2) 3 (30) 15 (31)
Septal fibrosis without cirrhosis 2 (20)  9 (18)
Cirrhosis 2 (20)  6 (12)
Portal inflammation n (%) n (%)
None 1 (10) - -
Mild 5 (50) 27 (55)
Moderate 4 (40) 19 (39)
Severe - -  3 (6)
HBV: Hepatitis B virus. P>0.05 for comparison of patients HBV-DNA(+)/HBV-DNA(-).
Response to treatment HBV-DNA (+) HBV-DNA (-)
n=44
n % n %
Sustained virological response 3 (37) 9 (21)
Biochemical response 1 (12) 11 (25)
Non-response 4 (50) 24 (55)
P>0.05 for comparison of patients HBV-DNA(+)/HBV-DNA(-).
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In co-infected patients, HBV and HCV may have
a low rate of replication, due to mutual interference
between these viruses [8,33-37). Some researchers
believe that HCV has a strong suppressive effect on
HVB replication [13,33,38-42], while others attribute
to HBV the dominant role as an inhibitor of replication.
[33 - 43]. It seems that inhibition of HBV replication
by HCV is more common than the opposite [44].
Occult HBV infection in HCV-infected patients has
been suggested as a possible co-factor, responsible
for both impaired response to interferon therapy [13,18]
and more severe liver disease [11,17,45,46].
In Italy, Cacciola et al., in a study of HCV-positive
patients who were HBsAg negative/anti-HBc positive,
were able to detect HBV-DNA in 46% of them. Liver
cirrhosis was diagnosed in 33% of the HCV-infected
patients who were HBV-DNA positive and in 19% of
the HBV-DNA negative HCV-infected patients [11].
They hypothesized that occult HBV infection could
favor or accelerate the evolution to cirrhosis in HCV-
positive patients [11,40]. Since cirrhosis is the most
important risk factor for the development of
hepatocellular carcinoma, a relation between HBV
occult infection and this complication should be
considered.
We found liver cirrhosis in 20% of the HBV-DNA-
positive patients and in 12% of the HBV-DNA negative
patients. However, there was no significant difference
between these two groups. Among our HCV-infected
patients, the histopathological lesions in the liver were
not more intense than in patients without occult HBV
infection. Other researchers [35,46-48] also observed
that occult HBV infection in HCV-infected patients does
not seem to be associated with more severe liver
disease. On the other hand, some researchers indicated
that anti-HBc (previous HBV infection), rather than
occult HBV infection, is associated with a worse
outcome in HCV-infected patients [35,46].
Differences among the populations, different
sensitivities of the assays used to detect HBV-DNA,
different types of specimen used to detect the presence
of HBV (serum or liver) and different prevalences of
HBV infection in the general population of various
countries, could explain the conflicting results. We were
not able to detect liver tissue markers (HBsAg and
HBcAg) in the HBV-DNA positive patients by
immunoperoxidase staining. The same was observed
i  Italian patients [11]. We consider that this could be
due to the very low HBV-DNA titers in the livers of
the patients, the low intrinsic sensitivity of the
immunohistochemical method, or because the HCV-
infected patients with occult HBV infection had only
residual replication outside of the liver.
Among oriental patients with occult HBV infection,
it was observed that they are more frequently infected
with HCV genotype 1b [13]. We did not find a
significant difference in the frequencies of HCV
genotypes in HCV-infected patients with or without
HBV-DNA. The same was observed for similar HCV-
positive patients in Italy [46].
A reduced response to interferon therapy has been
described in individuals with chronic hepatitis C and
serological markers of a resolved HBV infection (HBsAg
negative/anti-HBc positive), perhaps due to an inapparent
HBV co-infection in these patients [18]. More recently,
some authors have observed that occult HBV infection
correlates with a lack of response to interferon treatment
in patients with chronic hepatitis C [11,18,45]. Cacciola
et al. detected a virological response in 21% and 42%
of HCV-positive patients who had an occult infection
with HBV or not, respectively [11]. We did not find a
significant difference in the virological response of HCV-
positive patients, with or without occult HBV infection
(37.5% and 20.5% respectively), when they were
treated with interferon alone, or associated with ribavirin.
The low levels of HBV-DNA in our patients did not
interfere in the response to therapy. The same was
observed in a recent study made in Taiwan with 110
patients who had chronic HCV infection. The prevalence
of occult HBV infection did not parallel the severity of
liver disease, and the sustained response to combination
therapy against HCV was comparable between patients
with or without occult HBV infection (38 versus 39%).
These researchers concluded that occult HBV infection
had no clinical significance in chronic hepatitis C [47].
Finally, we emphasize the high prevalence of occult
HBV infection (14%) among our Brazilian patients with
chronic hepatitis C who were HBsAg negative/ anti-
Occult B Infection in Chronic HCV Patients
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HBc positive when compared with the prevalence
observed in HBsAg negative/anti-HBc positive/HCV
negative blood donors (5.4%). We did not find an
association among the risk factors to acquire both
B and C viruses with higher rates of occult HBV
infection. No significant association was found
between more severe grades of liver fibrosis or
cirrhosis in HCV-infected patients and HBV-DNA
in sera. The SRV rates obtained with interferon
therapy in HCV-positive patients apparently were
not affected by occult HBV infection. New studies
should be made to determine if occult HBV
infection, with low levels of HBV-DNA, can
accelerate the natural course of chronic hepatitis C
and influence the response to therapy.
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